Nothing Special   »   [go: up one dir, main page]

WO1996025053A1 - Stabilizing agent for oleaginous, physiologically active substances - Google Patents

Stabilizing agent for oleaginous, physiologically active substances Download PDF

Info

Publication number
WO1996025053A1
WO1996025053A1 PCT/JP1996/000235 JP9600235W WO9625053A1 WO 1996025053 A1 WO1996025053 A1 WO 1996025053A1 JP 9600235 W JP9600235 W JP 9600235W WO 9625053 A1 WO9625053 A1 WO 9625053A1
Authority
WO
WIPO (PCT)
Prior art keywords
oily
dha
preparation
calcium
substance
Prior art date
Application number
PCT/JP1996/000235
Other languages
French (fr)
Japanese (ja)
Inventor
Kiyoshi Kumabe
Hiroyuki Yanaka
Takayuki Kondo
Jun Shirai
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Priority to US08/875,601 priority Critical patent/US5853761A/en
Publication of WO1996025053A1 publication Critical patent/WO1996025053A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463—Organic compounds; Microorganisms; Enzymes
    • A23L3/3481—Organic compounds containing oxygen
    • A23L3/3508—Organic compounds containing oxygen containing carboxyl groups
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a stabilizer for an oily bioactive substance and a preparation containing the same.
  • oily physiologically active substances such as DHA
  • methods of assisting ingestion include encapsulating them in capsules or adsorbing them on other powders and then coating them.
  • these are often inadequate in stability, or have large granules and tablets after processing, making them completely unsuitable for addition to general foods.
  • a method for forming a canola shell based on milk canopy is used to develop a chao (New Food Industry 1994, vol. 36, No. 9, 38— 42)
  • a chao New Food Industry 1994, vol. 36, No. 9, 38— 42
  • the present inventors have conducted intensive research to solve the above-mentioned problems. As a result, we have obtained new findings that calcium gluconate is extremely excellent as a stabilizer for oily bioactive substances. When used in combination with a matrix forming agent and / or a fixing agent, it was found that an extremely stable formulation without the above-mentioned problems could be obtained. Issued.
  • calcium dalconate is a relatively water-soluble calcium agent.
  • 100 g is added to one liter of water, about 30 g is dissolved, and 70 g is dissolved. The position is hazy.
  • an oily physiologically active substance is added to this liquid and stirred and emulsified, calcium that is not dissolved in water is adsorbed on the surface of the oil droplet to form a shell.
  • the dissolved calcium dalconate enters the gaps between the shell-forming particles and fills the holes.
  • a reticulated matrix-forming agent and / or a fixing agent further enhances the stability of the preparation. It has been found that a stable preparation without odor can be obtained even when the preparation obtained in this way is added to a linking agent or the like.
  • the oily bioactive substance used and applied in the present invention is an oily bioactive substance that has a peculiar off-flavor and off-flavor, and is unstable to enzymes, oxygen, light, heat, etc. Substances are mentioned as particularly preferred examples, such as DHA (docosahexaenoic acid) and EPA (eicosupenterpene). Polyunsaturated fatty acids), fat-soluble vitamins such as vitamin D, vitamin E and vitamin K, and carotines such as Are mentioned.
  • DHA, EPA, etc. are abundantly contained in fish oil and usually exist as triglycerides.However, when DHA and EFA are referred to in the present invention, DHA and EPA are also included. Includes glycerin esters (eg, triglycerides) of DHA and EPA, and estenore such as ethyl estenole.
  • glycerin esters eg, triglycerides
  • estenore such as ethyl estenole.
  • reticulated matrix-forming agent examples include minolec canoleum, minolec casein, or a hydrolyzate thereof [for example, casein and proteolytic enzymes (for example, Casein phosphopeptide (CPP) (CPP-I, CPP-II, CPP-III, etc.), which is a partially degraded product obtained by the action of phosphine) (New Food Industry Vol.35 No. .9 (1993), P. 1-8)), and polysaccharides such as actin.
  • minolec canoleum and CPP are reticulated matrices. It has a function of forming a matrix and also functions as a fixing agent, which will be described later, so that these can be used also as a network matrix forming agent and a fixing agent. You.
  • the fixing agent examples include a thickening agent (for example, CM starch, dextrin, pullulan, arabic gum, etc.) and a genole agent (for example, gelatin and carrageenan). , Alginate or the like alone or as a mixture).
  • the stabilizer for an oily bioactive substance comprising calcium or calcium gluconate or calcium dalconate and a reticulate matrix forming agent and a fixing agent according to the present invention is used as it is. It can be obtained by adding or mixing a preparation alone or with an arbitrary carrier to an oily physiologically active substance and preparing various preparations by a conventional method.
  • preparation containing an oily physiologically active substance examples include ordinary solid preparations such as powders (powder), spherical granules, fine granules, granules, tablets and capsules.
  • a dispersing agent such as xanthan gum, lecithin, yogurt, sucrose fatty acid ester, and glycerin fatty acid ester. Often.
  • the amount of calcium dalconate used is about 20-90% (% by weight, the same applies hereinafter), preferably about 50-90%, in the preparation.
  • the amount of the reticulated matrix forming agent is preferably 1 to 20%, and the amount of the fixing agent is preferably about 0.2 to 8%.
  • reticulated matrix forming agent for example, CPP
  • Mixing agents such as santum gum and lecithin
  • dispersants for example, CPP
  • an oily physiologically active substance for example, fish oil containing DHA
  • calcium dalconate and a fixing agent were added, and the mixture was passed through a vigorous stirring or high-pressure homogenizer (this).
  • the zeta level is set to not less than 30 mV, preferably to not less than 100 mV).
  • drying methods such as ordinary ventilation, vacuum, freezing, and spraying are applied.
  • Test Example 2 As in Test Example 1, the DHA-containing preparation of the present invention (the preparation obtained in Example 1) and the conventional preparation (same as in Test Example 1) were added. Jelly was produced, and the intensity of both fish odors was evaluated by sensory tests.
  • the fish odor to which the DHA preparation of the present invention is added is conventionally known. It was clearly improved compared to the known DHA preparation-added group.
  • Test example 3 The fish odor to which the DHA preparation of the present invention is added is conventionally known. It was clearly improved compared to the known DHA preparation-added group.
  • the DHA-containing preparation of the present invention (the preparation obtained in Example 1) and the conventional preparation (same as that in Test Example 1) were added to bean jam, respectively.
  • the soymilk to which the DHA-containing preparation of the present invention has been added has a distinctly lower fish odor and a higher concentration than the conventional preparation-added section. It can be seen that addition is possible.
  • the vitamin-E-containing preparation of the present invention (the preparation obtained in Example 4) and the conventionally known vitamin-E-containing preparation obtained by the following method were respectively added to milk and drink yolk. Addition of 1.25 g (100 mg as vitamin E) per 100 g of glut (Meiji Dairy Industries "Bulgaria no yogurt") to the beverage, without adding texture The plot was evaluated as a control. In addition, the formation of a precipitate was visually observed after the beverage was allowed to stand at 4 for 24 hours.
  • Example 4 Milk Calcium Powder ("Edible Ginseng Calcium Powder” manufactured by Health America, Inc.) was used instead of calcium dalconate as the shell-forming substance in Example 4.
  • a powder preparation containing vitamin E was produced in the same manner as in Example 4.
  • the test section to which the powder formulation containing vitamin E according to the present invention was added had a better texture and a precipitate was formed as compared with the powder formulation containing vitamin E produced by the conventional technique. It is said to be excellent in that it does not.
  • the DHA preparation of the present invention (the preparation obtained in Example 1) and the conventional preparation (the same as in Test Example 1) were placed in beakers, respectively, and opened for 2 months at 30 ° C and 90% humidity. After storage, the DHA content and peroxide value (P0V) were measured.
  • the DHA preparation of the present invention has better oxidative stability than conventional preparations.
  • the preparation according to the present invention is more excellent in masking properties and water affinity than the conventionally known preparations, and has no bad smell even when added to a drinking agent.
  • the preparation of the present invention can be used as the preparation itself or added to various foods. Especially since it does not generate a bad smell even when added to various beverages, it can be widely used in foods and drinks.
  • the preparation of the present invention since the preparation of the present invention has calcium supplementation and intestinal bifidobacteria activities in addition to the physiological action based on each physiologically active substance, it is useful as a health food. is there.
  • Casein hoshopeptide and Meiji CPP-I (trade name, manufactured by Meiji Seika Co., Ltd.) in 3,000 kg of purified water 160 kg, xanthan 1.3 kg of gum, 8.5 kg of lecithin, 1.8 kg of a mixture (9: 1) of gelatin and carrageenan as a fixing agent were mixed (stirred at 700-1.500 rpm), Dissolve. Then, 170 kg of DHA-containing fish oil (manufactured by Harima Chemicals, Inc., DHA content: 23%) is charged into the mixture, and pre-emulsified at a rotation speed of 2,000 to 5, OOOrpm.
  • Example 2 Production was carried out under the same conditions as in Example 1 except that 190 kg of purified fish oil containing 40% EPA was used instead of the DHA-containing fish oil in Example 1, and 845 kg of EPA-containing powder was obtained.
  • Example 2 Production was carried out in the same manner as in Example 1 except that 120 kg of soybean oil (manufactured by Rossch Co., Ltd.) containing 20% of ⁇ -carotin was used instead of the fish oil containing DHA in Example 1. 9 623 kg of powder containing rotin was obtained.
  • Minolec Calcium Powder (Health Way Co., Ltd.'s edible syrup powder) in 70 g of purified water as a matrix forming agent on the net , 0.04 g of xanthan gum, 0.25 g of lecithin and 1.2 g of dextrin are mixed and stirred.
  • One Ide was charged with bi data Mi emissions D 3 6.0 g in a mixture, you spare ⁇ to have use a high-speed host mode mixer.
  • Guru co Nsanka Honoré shea ⁇ beam powder 21.01 g was ⁇ fast e mode mixer, emulsion and hot-air dried, the bi data Mi emissions D 3 containing powder manufactured agent about 30 g Obtained.
  • 0.75 g of actin, 0.02 g of xanthan gum, 0.13 g of lecithin, and 0.6 g of sodium anoregate are mixed in 85 g of purified water, and mixed with stirring. Then, put 3.0 g of raw royal jelly into the mixture, and reserve with a high-speed homomixer? L. Finally, 10.5 g of canolecum dalconate powder was added, and the mixture was emulsified with a high-speed homomixer.The emulsion was dried with hot air to obtain about 13 g of a royal jelly-containing powder formulation. .
  • xanthan gum 0.04 g of xanthan gum, 0.25 g of lecithin, 6.0 g of fish oil containing DHA (DHA content 20%) in 70 g of purified water, 22.51 g of calcium dalconate powder and zera 1.2 g of a mixture of tin, punolen and K-carrageenan (13.2: 12.0: 1.3) And then emulsified with a high-speed homomixer. The solution was dried with hot air to obtain about 30 g of a DHA-containing powder preparation.
  • a stable preparation of an oily bioactive substance can be obtained by using calcium dalconate. Even if added, it is a stable formulation without odor and is useful.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

A solid preparation comprising an oleaginous, physiologically active substance, calcium gluconate, a reticular matrix forming agent and a sticking agent. It is a stable preparation that does not emit any odor even when added to drinkable preparations.

Description

明 細 書 発明の名称  Description Name of Invention
油状生理活性物質の安定化剤 技術分野  Stabilizers for oily bioactive substances
こ の発明は油状生理活性物質の安定化剤、 それを含有 す る製剤に関する ものであ る。 背景技術  The present invention relates to a stabilizer for an oily bioactive substance and a preparation containing the same. Background art
従来油状の生理活性物質 （例えば DHA等） は取扱いに く く 、 服用を助ける方法と してカプセルに封入するか、 他の粉体に吸着させた後コ ーティ ングを施すな どの方法 が行われて い たが、 こ れ ら は安定性が不十分であ っ た り 、 加工後の顆粒、 錠剤な どが大き く 、 一般食品への添 加には全 く 不適当であ る場合が多かっ た。 こ の問題を解 決すべ く ミ ル ク カ ノレ シ ゥ ム を 主体 と し た カ ノレ シ ゥ ム殻 形成法カオ開発された力 ( New Food Industry 1994, vol . 36, No.9, 38— 42 ) 、 こ の方法で得 られた製剤で も 、 こ れを例えば ド リ ン ク剤に添加使用する場合には不安定で 臭い等が出て く る と い う 問題点があ り 、 解決されるべき 課題であ る。 発明の開示  Conventionally, oily physiologically active substances (such as DHA) are not easy to handle, and methods of assisting ingestion include encapsulating them in capsules or adsorbing them on other powders and then coating them. However, these are often inadequate in stability, or have large granules and tablets after processing, making them completely unsuitable for addition to general foods. Was. In order to solve this problem, a method for forming a canola shell based on milk canopy is used to develop a chao (New Food Industry 1994, vol. 36, No. 9, 38— 42) However, even with the preparation obtained by this method, there is a problem that when it is added to, for example, a drink, it is unstable and produces an odor. This is an issue to be addressed. Disclosure of the invention
こ の発明者等は、 上記課題解決のため、 鋭意研究の結 果、 グルコ ン酸カ ル シ ウ ムが油状生理活性物質の安定化 剤 と して極めて優れて い る と い う 新知見 を得、 さ ら に こ のダルコ ン酸カ ル シ ウ ム と 網状マ ト リ ッ タ ス形成剤お よ び （ ま たは ） 固着剤 と を併用す る と 、 前記問題点を有 し な い極めて安定な製剤を得 る こ と がで き る こ と を見出 し た。 The present inventors have conducted intensive research to solve the above-mentioned problems. As a result, we have obtained new findings that calcium gluconate is extremely excellent as a stabilizer for oily bioactive substances. When used in combination with a matrix forming agent and / or a fixing agent, it was found that an extremely stable formulation without the above-mentioned problems could be obtained. Issued.
即ち ダル コ ン酸カ ルシ ウ ム は比較的水溶性の高いカル シ ゥ ム 剤で、 水 1 リ ツ ト ノレ中 に 1 00 g を投入 し た場合、 30 g 程度は溶解 し、 7 0 g 位は憑濁 し て い る 。 こ の液に油 状生理活性物質を加 え て撹拌、 乳化す る と 、 水に溶けて な い カ ル シ ウ ムは油滴の表面に吸着 し、 殻を形成する。 溶けて い る ダルコ ン酸カル シ ウ ム は殻形成粒子の間隙に 入 り 込み穴を う め る 。 こ の よ う な状態の混合液を速やか に乾燥す る と 、 油状生理活性物質が完全にマ ス ク された 粉体が出来 る と い う 新知見 を得た。  That is, calcium dalconate is a relatively water-soluble calcium agent. When 100 g is added to one liter of water, about 30 g is dissolved, and 70 g is dissolved. The position is hazy. When an oily physiologically active substance is added to this liquid and stirred and emulsified, calcium that is not dissolved in water is adsorbed on the surface of the oil droplet to form a shell. The dissolved calcium dalconate enters the gaps between the shell-forming particles and fills the holes. New knowledge has been obtained that if the mixed solution in such a state is dried quickly, a powder completely masked with the oily bioactive substance can be obtained.
そ して さ ら に上記ダルコ ン酸カルシ ウ ム に加 えて、 網 状マ ト リ ッ ク ス形成剤お よ び （ ま たは ） 固着剤を併用す る と 製剤の安定性がさ ら に向上 し、 こ の よ う に して得 ら れた製剤を ド リ ン ク 剤等に添加 して も 臭いのな い安定な 製剤が得 られる こ と を見出 し た。  In addition to the calcium dalconate described above, the use of a reticulated matrix-forming agent and / or a fixing agent further enhances the stability of the preparation. It has been found that a stable preparation without odor can be obtained even when the preparation obtained in this way is added to a linking agent or the like.
こ の発明で使用、 適用 さ れる 油状生理活性物質 と して は、 油状の生理活性物質であ っ て、 特有の異味、 異臭を 有 し、 ま た酵素、 酸素、 光、 熱等に不安定な物質がと く に好 ま し い例 と し て 挙げ ら れ、 そ の よ う な具体例 と し て、 D H A ( ド コ サへキサェ ン酸） 、 E P A (エイ コ サペン タ ェ ン酸） 等の高度不飽和脂肪酸、 ビ タ ミ ン D、 ビタ ミ ン E お よびビタ ミ ン K等の脂溶性ビタ ミ ン、 ー カ ロ チ ン の よ う なカ ロ チ ン類等が挙げ られる。 The oily bioactive substance used and applied in the present invention is an oily bioactive substance that has a peculiar off-flavor and off-flavor, and is unstable to enzymes, oxygen, light, heat, etc. Substances are mentioned as particularly preferred examples, such as DHA (docosahexaenoic acid) and EPA (eicosupenterpene). Polyunsaturated fatty acids), fat-soluble vitamins such as vitamin D, vitamin E and vitamin K, and carotines such as Are mentioned.
こ こ で、 DHA、 EPA等は魚油中に多 く 含まれ、 通常 ト リ グ リ セ ラ イ ド と して存在するが、 こ の発明で DHA、 EFAと い う 場合、 DHA、 EPAその も のお よび DHA、 EPAそれぞれの グ リ セ リ ンエ ス テ ル （例えば ト リ グ リ セ ラ イ ド ） 、 ェチ ルエス テノレ等のエス テノレ等を含む も の と する。  Here, DHA, EPA, etc. are abundantly contained in fish oil and usually exist as triglycerides.However, when DHA and EFA are referred to in the present invention, DHA and EPA are also included. Includes glycerin esters (eg, triglycerides) of DHA and EPA, and estenore such as ethyl estenole.
ま た、 DHAや EPAは こ れ ら を 20~ 100%含有の精製魚油 が市販されてお り 、 こ れ ら を使用する こ と がで き る。  For DHA and EPA, refined fish oils containing 20 to 100% of these are commercially available, and these can be used.
こ の発明で使用す る 網状マ ト リ ッ ク ス形成剤 と して は、 ミ ノレク カノレシ ゥム、 ミ ノレク カゼイ ン ま たはその水解 物 [例えば、 カゼイ ン に蛋白分解酵素 （例えば ト リ プシ ン ） を 作用 さ せて得 ら れ る部分分解物であ る カ ゼイ ン ホス ホペプチ ド （ CPP) ( CPP— I 、 CPP— I I、 CPP— I I I 等） ( New Food Indust ry Vol .35 No.9( 1993), P. 1 - 8 ) 等] 、 ぺク チ ンの よ う な多糖類等が挙げられ、 これ ら の う ち、 ミ ノレ ク カ ノレ シ ゥ ム、 CPPは網状マ ト リ ッ ク ス 形成能を有する と と も に、 後述の固着剤 と しての機能を 有す るので、 これ ら は網状マ ト リ ッ ク ス形成剤お よび固 着剤 と して兼用でき る。  Examples of the reticulated matrix-forming agent used in the present invention include minolec canoleum, minolec casein, or a hydrolyzate thereof [for example, casein and proteolytic enzymes (for example, Casein phosphopeptide (CPP) (CPP-I, CPP-II, CPP-III, etc.), which is a partially degraded product obtained by the action of phosphine) (New Food Industry Vol.35 No. .9 (1993), P. 1-8)), and polysaccharides such as actin. Among these, minolec canoleum and CPP are reticulated matrices. It has a function of forming a matrix and also functions as a fixing agent, which will be described later, so that these can be used also as a network matrix forming agent and a fixing agent. You.
ま た、 固着剤 と して は、 增粘剤 （例えば、 CM デン プ ン、 デキ ス ト リ ン、 プルラ ン、 ア ラ ビアガム等） 、 ゲ ノレ剤 （例えば、 ゼラ チ ン、 カ ラ ギナ ン、 アルギン酸塩等 の単独ま たは混合物等） 等が挙げられる。 こ の発明のグルコ ン酸カル シ ウ ム あ る い はダルコ ン酸 カルシウム と 網状マ ト リ ッ ク ス形成剤お よび固着剤と を 含有する油状生理活性物質の安定化剤は、 その ま ま単独 あ る い は任意の担体 と の製剤を油状生理活性物質に添 加、 混合 し、 常法に よ り 各種の製剤 と して得る こ とがで き る。 Examples of the fixing agent include a thickening agent (for example, CM starch, dextrin, pullulan, arabic gum, etc.) and a genole agent (for example, gelatin and carrageenan). , Alginate or the like alone or as a mixture). The stabilizer for an oily bioactive substance comprising calcium or calcium gluconate or calcium dalconate and a reticulate matrix forming agent and a fixing agent according to the present invention is used as it is. It can be obtained by adding or mixing a preparation alone or with an arbitrary carrier to an oily physiologically active substance and preparing various preparations by a conventional method.
油状生理活性物質含有製剤と しては、 散剤 （粉末） 、 球型粒、 細粒剤、 顆粒剤、 錠剤、 カプセル剤等の通常の 固形製剤が挙げ ら れ る 。  Examples of the preparation containing an oily physiologically active substance include ordinary solid preparations such as powders (powder), spherical granules, fine granules, granules, tablets and capsules.
こ の発明の油状生理活性物の固形製剤を製造する場合 には必要に よ り 、 通常の希釈剤、 賦形剤、 崩壊剤等を使 用する こ と がで き る 。  When the solid preparation of the oily physiologically active substance of the present invention is produced, a usual diluent, excipient, disintegrant and the like can be used as necessary.
ま た、 キサ ン タ ンガム、 レ シチ ン、 ヨ ー グル ト 、 蔗糖 脂肪酸エ ス テ ル、 グ リ セ リ ン脂肪酸エス テ ル等の扎化 剤、 分散剤を使用する と好結果が得 られる こ と が多い。  In addition, good results can be obtained by using a dispersing agent such as xanthan gum, lecithin, yogurt, sucrose fatty acid ester, and glycerin fatty acid ester. Often.
ダルコ ン酸カル シ ウ ムの使用量は、 製剤中、 20~ 90% ( 重量％、 以下同 じ ） 、 好ま し く は 50〜 90%程度であ る。  The amount of calcium dalconate used is about 20-90% (% by weight, the same applies hereinafter), preferably about 50-90%, in the preparation.
網状マ ト リ ッ ク ス形成剤の使用量は、 1 ~ 20%、 固着 剤の使用量は 0.2〜 8 %程度が好ま しい。  The amount of the reticulated matrix forming agent is preferably 1 to 20%, and the amount of the fixing agent is preferably about 0.2 to 8%.
こ の発明の油状生理活性物質、 ダル コ ン酸カルシウム な らびに網状マ ト リ ッ ク ス形成剤お よび （ ま たは） 固着 剤を含有する製剤 （粉剤） の製造例を示す と、 次の通 り であ る。  Examples of the production of a preparation (powder) containing the oily physiologically active substance, calcium dalconate and reticulated matrix-forming agent and / or fixing agent of the present invention are shown below. It is as follows.
精製水に網状マ ト リ ッ ク ス形成剤 （例えば CPP) 、 キ サ ン タ ン ガム 、 レ シ チ ン等の扎化剤、 分散剤を混合す る 。 次いで油状生理活性物質 （例えば DHA含有魚油） を 投入 し、 撹抨、 混合 したあ と 、 ダルコ ン酸カル シ ウム及 び固着剤を加え、 強撹拌ま たは高圧ホモゲナイ ザーに通 し た （ こ れ ら の処理 に よ り 、 ゼー タ ー窀位を 一 30mV以 上、 好 ま し く は - lOOmV以上にす る ） あ と 、 乾燥粉末化 する。 Add reticulated matrix forming agent (for example, CPP), Mixing agents such as santum gum and lecithin, and dispersants. Next, an oily physiologically active substance (for example, fish oil containing DHA) was added, and after stirring and mixing, calcium dalconate and a fixing agent were added, and the mixture was passed through a vigorous stirring or high-pressure homogenizer (this). With these treatments, the zeta level is set to not less than 30 mV, preferably to not less than 100 mV).
こ こ で乾燥は、 通常の通風、 真空、 凍結、 噴霧等の乾 燥法が適用 される。  Here, drying methods such as ordinary ventilation, vacuum, freezing, and spraying are applied.
次に こ の発明の製剤 と 従来品 と の比較を試験例に よ り 説明す る。  Next, a comparison between the formulation of the present invention and a conventional product will be described based on test examples.
試験例 1 ： Test example 1:
こ の発明の製剤 ： 実施例 1 で得 られた製剤 Formulation of this invention: Formulation obtained in Example 1
従来の製剤 ： 下記の方法で得 られた製剤 Conventional formulation: A formulation obtained by the following method
精製 DHA含有魚油 （ DHAを 27%含有） 100 g と、 200メ ッ シ ュ 下の ミ ル ク カル シ ウ ム微粉末 （株式会社ヘルス ゥ ヱ ィ 製の 「食用乳清カルシ ウ ム粉」 ） 300 g と、 水 1.0リ ツ ト ルを ビーカーに入れ、 高速ホモ ジナイ ザーに よ り 8000 rpmで 10分間撹抨 した。 次いで、 0.3%アルギン酸ナ ト リ ゥ ム水溶液 200mlを添加 し、 2000 rpmで 5 分間撹拌 した。  100 g of refined DHA-containing fish oil (containing 27% DHA) and fine powder of milk calcium under 200 mesh ("Edible Whey Calcium Powder" manufactured by Health Pharma Inc.) 300 g and 1.0 liter of water were put into a beaker, and the mixture was stirred at 8000 rpm for 10 minutes by a high-speed homogenizer. Next, 200 ml of a 0.3% aqueous sodium alginate solution was added thereto, followed by stirring at 2000 rpm for 5 minutes.
そ の後に、 噴霧乾燥機を使用 し、 入 口温度 120。C以下 で処理す る こ と に よ り DHA含有精製魚油封入カル シ ウム 微粒子 180 g を得た。 [表 1 ] 比較項目 の発明の製剤 従来の製剤 様状 白色粉末 黄みを帯びた白色末 粒度（ハシュ） 1 1 0 1 7 0 保存安定性 1 年以上 1年以上 The inlet temperature is then 120 using a spray dryer. By treating with C or lower, 180 g of calcium fine particles containing DHA-containing purified fish oil were obtained. [Table 1] Formulation of invention of comparative item Conventional formulation Appearance White powder Yellowish white powder Particle size (Hash) 1 1 0 1 7 0 Storage stability 1 year or more 1 year or more
(常温） 熱安定性 1 5 0 'C— 1 0分 2 0 0 'C— 1 5分  (Normal temperature) Thermal stability 1 5 0 'C-10 min 2 0 0' C-15 min
(分解） (分解） 水への溶解性 可なりの部分が溶解 不溶  (Decomposition) (Decomposition) Solubility in water A considerable part dissolves Insoluble
速やかに分散する 水中懋«性 良好（数日沈殿せず） 2 〜 3時間で沈殿 加工特性 食品全般の加工に 練り込み、 焼き込み  Quickly disperses in water Good in water (No sedimentation for several days) Sedimentation in 2 to 3 hours Processing characteristics Kneading and baking in all food processing
jf 及打綻性に優れる ドリ ンクへ応用 悪い臭いも味もなく 魚臭 ·味がでる  jf Applied to drinks with excellent crushing property No bad smell or taste Fish smell
食感よ し ざらつき感ぁり  Texture and texture
[表 2 ] 水、 牛乳およびヨーグル トそれぞれ l OOcc中に 各製剤を添加しても魚臭、 魚味の感じられない 限界量 （カツコ内の数値は DHAに換算したもの） この 明の製剤 従来の製剤 [Table 2] Water, milk, and yogurt Each limit of the amount of fish odor and fish taste not perceived even when added to each OOcc (the values in Katsuki are converted to DHA). Formulation of
( mg ) ( mg)  (mg) (mg)
水 5 0 0 ( 2 0 ) 1 2 5 ( 5 ) 牛乳 2 , 5 0 0 ( 1 0 0 ) 2 5 0 ( 1 0 ) ョーグル ト 5 , 0 0 0 ( 2 0 0 ) 3 7 5 ( 1 5 ) 試験例 2 試験例 1 と同様に本発明の DHA含有製剤 （実施例 1で得られた 製剤） と従来の製剤 （試験例 1 のものと同じ） をそれぞれ添加し たゼリーを製造し、 両者の魚臭の強さを官能検査によ り評価しWater 5 0 0 (2 0) 1 2 5 (5) Milk 2, 5 0 0 (1 0 0) 2 5 0 (1 0) Yogurt 5, 0 0 0 (2 0 0) 3 7 5 (1 5 ) Test Example 2 As in Test Example 1, the DHA-containing preparation of the present invention (the preparation obtained in Example 1) and the conventional preparation (same as in Test Example 1) were added. Jelly was produced, and the intensity of both fish odors was evaluated by sensory tests.
(ゼリーの組成）(Jelly composition)
Figure imgf000009_0001
Figure imgf000009_0001
注） D H Aと して約 3 0 m g / 1 0 0 β Note) About 30 mg / 100 β as DHA
(ゼ リ ーの製造法） グラ ニ ュ ー糖、 カ ラ ギナ ン、 第 1 リ ン酸カ リ ウム、 ク ェ ン酸ナ ト リ ウ ム、 D H A製剤 を あ ら か じめ よ く 混合 して お き 、 こ れに半量の水 を加え て粉末 を よ く 分散 させる。 次に濃縮 ジュ ース と 残 り の水 を混合 し た も の を加え、 85 'C 以上に加熱 し完全に溶解させた後荒熱を取 り 、 容器に 移 し、 冷却 してゼ リ ー を調製 した。 (官能検査の方法） 無添加区のゼ リ ー を対照に下記の基準で評価 した。 パ ネ ノレ数 1 0 (Manufacturing method of jelly) Granular sugar, carrageenan, potassium diphosphate, sodium citrate, and DHA preparation are mixed in advance. Then, add half the amount of water and disperse the powder well. Next, a mixture of concentrated juice and the remaining water is added, and the mixture is heated to 85'C or more to completely dissolve the solution, remove the rough heat, transferred to a container, cooled, and cooled. Was prepared. (Method of sensory test) The jelly in the non-added section was evaluated as a control according to the following criteria. Number of panels 1 0
評価点  Evaluation points
対照区 と 差な し （ 魚臭な し ） 0 対照区に比べやや魚臭を感 じ る 1 対照区に比べ少 し魚臭を感 じ る 2 対照区に比べかな り 魚臭を感 じ る 3 対照区に比べ非常に魚臭を感 じ る 4  No difference from control group (no fish odor) 0 Fewer fish odor than control group 1 Fewer fish odor than control group 2 Feel fish odor compared to control group 3 Feels very fishy compared to control 4
(結果） (Result)
[表 4 ] 表 4 [Table 4] Table 4
Figure imgf000010_0001
こ の発明の D H A製剤 を 添加 し たゼ リ 一の魚臭は従来公 知の DHA製剤添加区に比べて明 らかに改善されて いた。 試験例 3
Figure imgf000010_0001
The fish odor to which the DHA preparation of the present invention is added is conventionally known. It was clearly improved compared to the known DHA preparation-added group. Test example 3
試験例 1 と 同様に本発明の DHA含有製剤 （実施例 1 で 得 られた製剤） と 従来の製剤 （試験例 1 の も の と 同 じ） をそれぞれ豆扎に添加 し、 魚臭の強さ を官能検査に よ り 評価 した。 （官能検査の方法）  As in Test Example 1, the DHA-containing preparation of the present invention (the preparation obtained in Example 1) and the conventional preparation (same as that in Test Example 1) were added to bean jam, respectively. Was evaluated by a sensory test. (Method of sensory test)
無添加区の豆乳を対照に試験例 2 と 同様の基準で評価 した。 パネル数 4  Using the soymilk in the non-added group as a control, the evaluation was performed in the same manner as in Test Example 2. Number of panels 4
(結果）  (Result)
[表 5 ]  [Table 5]
Figure imgf000011_0001
Figure imgf000011_0001
注） 表中の数値は評価点の平均値  Note) The figures in the table are the average of the evaluation points
こ の発明の DHA含有製剤を添加 した豆乳は、 従来の製 剤添加区に比べて、 魚臭は明 らかに弱 く 、 よ り 高濃度の 添加が可能であ る こ と が分かる。 The soymilk to which the DHA-containing preparation of the present invention has been added has a distinctly lower fish odor and a higher concentration than the conventional preparation-added section. It can be seen that addition is possible.
試験例 4 Test example 4
こ の発明の ビタ ミ ン E含有製剤 （実施例 4 で得 られた 製剤） と 下記の方法で得 られた従来公知の ビタ ミ ン E含 有製剤をそれぞれ牛乳お よ び ド リ ン ク ヨ ー グル ト （明治 乳業 「ブルガ リ ア のむ ヨ ー グル ト 」 ） に 100 g 当 り 1.25 g ( ビタ ミ ン E と して lOOrag) 添加 し た時の飲料のにお い、 食感を無添加区を対照に評価 した。 ま た、 沈澱物の 生成については、 飲料を 4 で で 2 4 時間静置 した後、 肉 眼で観察 した。  The vitamin-E-containing preparation of the present invention (the preparation obtained in Example 4) and the conventionally known vitamin-E-containing preparation obtained by the following method were respectively added to milk and drink yolk. Addition of 1.25 g (100 mg as vitamin E) per 100 g of glut (Meiji Dairy Industries "Bulgaria no yogurt") to the beverage, without adding texture The plot was evaluated as a control. In addition, the formation of a precipitate was visually observed after the beverage was allowed to stand at 4 for 24 hours.
(従来のビタ ミ ン E含有製剤）  (Conventional formulation containing vitamin E)
実施例 4 におけ る殻形成物質 と してダル コ ン酸カルシ ゥ ムの代 り に ミ ルク カルシ ウ ム粉末 （株式会社ヘルス ゥ エイ 製の 「食用扎清カル シ ウ ム粉」 ） を使用 して、 実施 例 4 と 同様の方法で ビ タ ミ ン E 含有粉末製剤を製造 し た。  Milk Calcium Powder ("Edible Ginseng Calcium Powder" manufactured by Health America, Inc.) was used instead of calcium dalconate as the shell-forming substance in Example 4. A powder preparation containing vitamin E was produced in the same manner as in Example 4.
(結果） (result)
[表 6 ] [Table 6]
Figure imgf000013_0001
Figure imgf000013_0001
こ の発明に よ る ビタ ミ ン E含有粉末製剤を添加 した試 験区は、 従来の技術で製造 した ビ タ ミ ン E含有粉末製剤 に比べて食感は良好であ り 、 沈澱物が生成 しない点でも 優れて い る と い え る。  The test section to which the powder formulation containing vitamin E according to the present invention was added had a better texture and a precipitate was formed as compared with the powder formulation containing vitamin E produced by the conventional technique. It is said to be excellent in that it does not.
試験例 5 Test example 5
本発明の DHA製剤 （実施例 1 で得 られた製剤） と従来 の製剤 （試験例 1 の もの と 同 じ ） をそれぞれビーカーに 採 り 、 開封状態で 30°C 、 湿度 90%で 2 ヶ 月 間保存 し、 DHA含量お よび過酸化物価 （ P0V) を測定 した。  The DHA preparation of the present invention (the preparation obtained in Example 1) and the conventional preparation (the same as in Test Example 1) were placed in beakers, respectively, and opened for 2 months at 30 ° C and 90% humidity. After storage, the DHA content and peroxide value (P0V) were measured.
(結果） (result)
[表 7 ] [Table 7]
Figure imgf000014_0001
Figure imgf000014_0001
こ の発明の DHA製剤は従来の製剤に比べて酸化安定性 も優れてレ、 る。  The DHA preparation of the present invention has better oxidative stability than conventional preparations.
以上の よ う に、 こ の発明に よ る製剤は従来公知の製剤 に比べ、 マス キ ン グ性、 水親和性に もす ぐれ、 ド リ ン ク 剤に添加 して も 悪い臭い も ない。  As described above, the preparation according to the present invention is more excellent in masking properties and water affinity than the conventionally known preparations, and has no bad smell even when added to a drinking agent.
こ の発明の製剤は、 製剤それ自体と して あ る いは各種 食品に添加 して使用する こ と ができ る。 と く に各種飲料 に添加 して も悪い臭いの発生がないので、 広 く 食品、 飲 料等に添加使用でき る。  The preparation of the present invention can be used as the preparation itself or added to various foods. Especially since it does not generate a bad smell even when added to various beverages, it can be widely used in foods and drinks.
ま た、 こ の発明の製剤は、 各生理活性物質に基づ く 生 理作用に加え て、 カルシ ウムの補給、 腸内 ビ フ ィ ズス菌 の活性を有するので、 健康食品 と して有用であ る。  In addition, since the preparation of the present invention has calcium supplementation and intestinal bifidobacteria activities in addition to the physiological action based on each physiologically active substance, it is useful as a health food. is there.
次にこ の発明の実施例を示す。  Next, examples of the present invention will be described.
実施例 1 ( DHA含有粉末の製造） Example 1 (Production of DHA-containing powder)
精製水 3， 000kg中に カ ゼ イ ン ホ ス ホペプチ ド、 明治 CPP - I (商品名， 明治製菓 （株） 製） 160kg, キサ ン タ ン ガ ム 1.3kg, レ シ チ ン 8.5kg、 固着剤 と し て ゼ ラ チ ン と カ ラ ギナ ン と の混合物 （ 9 ： 1 ) 1.8kgを混合 （ 700〜 1. 500 rpm. で撹拌） 、 溶解す る 。 つ い で DHA含有魚油 (ハ リ マ化成 （株） 製、 DHA含量 23% ) 170kgを混液中に 投入 し、 2， 000~ 5， OOOrpm. の回転数で予備乳化する。 最後に ダル コ ン酸カ ル シ ウ ム微粉末 650kgを加 え 1, 000 rpm.で撹拌 した後、 高圧ホ モ ゲナイ ザーを ZOOkg/ cm2 の加圧下に通過させてか ら ノ ズル型噴霧乾燥機にて粉末 化 して、 DHA含有粉末製剤 810kgを得た。 Casein hoshopeptide and Meiji CPP-I (trade name, manufactured by Meiji Seika Co., Ltd.) in 3,000 kg of purified water 160 kg, xanthan 1.3 kg of gum, 8.5 kg of lecithin, 1.8 kg of a mixture (9: 1) of gelatin and carrageenan as a fixing agent were mixed (stirred at 700-1.500 rpm), Dissolve. Then, 170 kg of DHA-containing fish oil (manufactured by Harima Chemicals, Inc., DHA content: 23%) is charged into the mixture, and pre-emulsified at a rotation speed of 2,000 to 5, OOOrpm. Finally after stirring the DAL co Nsanka Le shea U beam powder 650kg pressurized example 1, 000 rpm., The high-pressure auxiliary motor a Genai Heather passed under pressure of ZOOkg / cm 2 in either et Bruno nozzle type spray It was pulverized with a dryer to obtain 810 kg of a DHA-containing powder preparation.
実施例 2 ( EPA含有粉末の製造） Example 2 (Production of EPA-containing powder)
実施例 1 における DHA含有魚油にかえて、 EPA40%を含 む精製魚油 190kgを使用 して、 実施例 1 と 全 く 同 じ条件 下で製造を行い、 EPA含有粉末 845kgを得た。  Production was carried out under the same conditions as in Example 1 except that 190 kg of purified fish oil containing 40% EPA was used instead of the DHA-containing fish oil in Example 1, and 845 kg of EPA-containing powder was obtained.
実施例 3 ( ー カ ロ チ ン含有粉末の製造） Example 3 (Production of powder containing carotene)
実施例 1 にお け る DHA含有魚油にか えて、 20%の ^ - カ ロ チ ン を含む大豆油 （ ロ ッ シ ュ （株） 製） 120kgを用 い実施例 1 と 同様に製造を行い 9 一 力 ロ チ ン含有粉末 623kgを得た。  Production was carried out in the same manner as in Example 1 except that 120 kg of soybean oil (manufactured by Rossch Co., Ltd.) containing 20% of ^ -carotin was used instead of the fish oil containing DHA in Example 1. 9 623 kg of powder containing rotin was obtained.
実施例 4 Example 4
精製水 70 g 中にカゼイ ンナ ト リ ウム 1.5 g 、 キサンタ ンガ厶 0.04 g 、 レ シチ ン 0.25 g お よ びゼラ チ ン、 プノレラ ン、 K 一 力 ラ ギナ ンの混合物 （ 13.2 : 12.0 ： 1.3) 1.2 g を入れ撹拌混合する。 ついで、 ビタ ミ ン E含有油 （ ビタ ミ ン E含量 40% ) 6 g を混液中に投入 し、 高速ホモ ミ キ サー を 用 い て 予備乳化す る。 最後にダル コ ン酸カ ルシ ゥ ム粉末 21. Ol g を 加 え 、 高速ホ モ ミ キサーで扎化 した 後、 扎化液を熱風乾燥 し、 ビタ ミ ン E 含有粉末製剤約 30 g を得た。 1.5 g of casein sodium, 0.04 g of xanthangam, 0.25 g of lecithin, and a mixture of gelatin, punorelane, and K-gluginin in 70 g of purified water (13.2: 12.0: 1.3) Add 1.2 g and mix with stirring. Next, 6 g of vitamin E-containing oil (vitamin E content 40%) is charged into the mixture, and pre-emulsified using a high-speed homomixer. Finally, Dalconic acid calcium After adding 21. Ol g of the umbilical powder and zoning with a high-speed homogenizer, the zonating solution was dried with hot air to obtain about 30 g of a vitamin E-containing powder preparation.
精製水 70 g 中 に網上マ ト リ ッ ク ス形成剤 と して ミ ノレ ク カ ル シ ウ ム粉末 （株式会社ヘルス ウェ イ 製の 「食用扎清 カ ノレ シ ゥ ム粉」 ） 1.5 g 、 キ サ ン タ ン ガム 0.04 g 、 レ シ チ ン 0.25 g 、 デキ ス ト リ ン 1.2 g を 入れ撹拌混合する。 つ いで、 ビ タ ミ ン D 3 6.0 g を混液中 に投入 し、 高速ホ モ ミ キサー を用 い て予備扎化す る 。 最後に グル コ ン酸カ ノレ シ ゥ ム粉末 21.01 g を 加 え、 高速 ホ モ ミ キサーで扎化 した後、 乳化液を熱風乾燥 し、 ビ タ ミ ン D 3 含有粉末製 剤約 30 g を得た。 1.5 g of Minolec Calcium Powder (Health Way Co., Ltd.'s edible syrup powder) in 70 g of purified water as a matrix forming agent on the net , 0.04 g of xanthan gum, 0.25 g of lecithin and 1.2 g of dextrin are mixed and stirred. One Ide was charged with bi data Mi emissions D 3 6.0 g in a mixture, you spare扎化to have use a high-speed host mode mixer. Finally while handling Guru co Nsanka Honoré shea © beam powder 21.01 g, was扎化fast e mode mixer, emulsion and hot-air dried, the bi data Mi emissions D 3 containing powder manufactured agent about 30 g Obtained.
実施例 6 Example 6
精製水 85 g 中にぺク チ ン 0.75 g 、 キサ ン タ ンガム 0.02 g 、 レ シ チ ン 0.13 g 、 ァ ノレ ギ ン酸ナ ト リ ウ ム 0.6 g を 入 れ撹拌混合す る 。 つ い で、 生 ロ ー ヤ ルゼ リ ー 3.0 g を混 液中 に投入 し、 高速ホ モ ミ キサーで予備？ L化す る。 最後 に ダル コ ン 酸 カ ノレ シ ゥ ム粉末 10.5 g を加 え、 高速ホ モ ミ キサ一 で乳化 し た後、 乳化液を熱風乾燥 し、 ロ ーヤルゼ リ ー含有粉末製剤約 13 g を得た。  0.75 g of actin, 0.02 g of xanthan gum, 0.13 g of lecithin, and 0.6 g of sodium anoregate are mixed in 85 g of purified water, and mixed with stirring. Then, put 3.0 g of raw royal jelly into the mixture, and reserve with a high-speed homomixer? L. Finally, 10.5 g of canolecum dalconate powder was added, and the mixture was emulsified with a high-speed homomixer.The emulsion was dried with hot air to obtain about 13 g of a royal jelly-containing powder formulation. .
実施例 7 Example 7
精製水 70 g 中にキサ ン タ ン ガム 0.04 g 、 レ シ チ ン 0.25 g 、 DHA含有魚油 （ DHA含量 20% ) 6.0 g 、 ダル コ ン酸カ ル シ ゥ ム粉末 22.51 g お よ びゼ ラ チ ン 、 プノレ ラ ン、 K一 カ ラ ギナ ンの混合物 （ 13.2 : 12.0 : 1.3) 1.2 g を一括投 入 し、 高速ホモ ミ キサーで乳化 した後、 ？し化液を熱風乾 燥 し D H A含有粉末製剤約 30 g を得た。 0.04 g of xanthan gum, 0.25 g of lecithin, 6.0 g of fish oil containing DHA (DHA content 20%) in 70 g of purified water, 22.51 g of calcium dalconate powder and zera 1.2 g of a mixture of tin, punolen and K-carrageenan (13.2: 12.0: 1.3) And then emulsified with a high-speed homomixer. The solution was dried with hot air to obtain about 30 g of a DHA-containing powder preparation.
産業上の利用可能性 Industrial applicability
以上の よ う に、 こ の発明はダルコ ン酸カルシウムを使 用する こ と に よ り 安定な油状生理活性物質の製剤を得る こ と ができ 、 該製剤は、 例えば ド リ ン ク 剤等の添加 して も 臭いのない安定な製剤であ り 有用であ る。  As described above, according to the present invention, a stable preparation of an oily bioactive substance can be obtained by using calcium dalconate. Even if added, it is a stable formulation without odor and is useful.

Claims

請求の範囲 The scope of the claims
1 . ダルコ ン酸カルシ ウム を含有する油状生理活性物質 の安定化剤。  1. Stabilizer of oily bioactive substance containing calcium dalconate.
2 . ダルコ ン酸カルシ ウムお よび網状マ ト リ ッ ク ス形成 剤を含有するか、 ま たはダルコ ン酸カ ル シ ウ ム 、 網状マ ト リ ッ ク ス形成剤お よ び固着剤を含有する油状生理活性 物質の安定化剤。  2. Contains calcium dalconate and reticulated matrix forming agent, or contains calcium dalconate, reticulated matrix forming agent and fixing agent. Stabilizer for oily bioactive substances contained.
3 . 油状生理活性物質 と ダル コ ン酸カ ル シ ウ ム と を含有 す る油状生理活性物質の固形製剤。  3. A solid preparation of an oily bioactive substance comprising an oily bioactive substance and calcium dalconate.
4 . 油状生理活性物質、 ダル コ ン 酸 カ ル シ ウ ムお よび網 状マ ト リ ッ ク ス形成剤を含有するか、 ま たは油状生理活 性物質、 ダルコ ン酸カルシウム、 網状マ ト リ ッ ク ス形成 剤お よ び固着剤を 含有す る 油状生理活性物質の固形製 剤。 4. It contains an oily bioactive substance, calcium dalconate and a reticulated matrix former, or contains an oily bioactive substance, calcium dalconate, reticulated matrices. A solid preparation of an oily physiologically active substance containing a liquid forming agent and a fixing agent.
5 . 油状生理活性物質 と ダル コ ン 酸カ ル シ ウ ム と を混合 撹拌 したあ と乾燥す る こ と を特徴 と する油状生理活性物 質の固形製剤の製造法。  5. A method for producing a solid preparation of an oily bioactive substance, comprising mixing and stirring an oily bioactive substance and calcium dalconate, followed by drying.
6 . 油状生理活性物質、 ダル コ ン酸カ ル シ ウ ム な ら びに 網状マ ト リ ッ ク ス形成剤お よび （ ま たは） 固着剤を混合 撹拌 したあ と乾燥する こ と を特徴 と する油状生理活性物 質の固形製剤の製造法。  6. It is characterized in that it is dried after mixing and stirring an oily physiologically active substance, calcium dalconate and reticulated matrix-forming agent and / or fixing agent. A method for producing a solid preparation of an oily bioactive substance.
7 . 油状生理活性物質が D H A含有魚油であ る請求項 1 の 安定化剤。  7. The stabilizer according to claim 1, wherein the oily physiologically active substance is fish oil containing DHA.
8 . 油状生理活性物質が D H A含有魚油であ る請求項 2 の 安定化剤。 8. The stabilizer according to claim 2, wherein the oily bioactive substance is DHA-containing fish oil.
9 . 油状生理活性物質が DHA含有魚油であ る請求項 3 の 固形製剤。 9. The solid preparation according to claim 3, wherein the oily physiologically active substance is DHA-containing fish oil.
10. 油状生理活性物質が DHA含有魚油であ る請求項 4 の 固形製剤。  10. The solid preparation according to claim 4, wherein the oily bioactive substance is DHA-containing fish oil.
11. 油状生理活性物質が DHA含有魚油、 網状マ ト リ ッ ク ス形成剤がカゼィ ン ホス ホぺプチ ド、 固着剤がゼラチ ン と カ ラ ギナ ンの混合物であ る請求項 4 の固形製剤 n 11. The solid preparation according to claim 4, wherein the bioactive oily substance is DHA-containing fish oil, the reticulate matrix forming agent is casein phosphopeptide, and the fixing agent is a mixture of gelatin and carrageenan. n
PCT/JP1996/000235 1995-02-13 1996-02-06 Stabilizing agent for oleaginous, physiologically active substances WO1996025053A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/875,601 US5853761A (en) 1995-02-13 1996-02-06 Stabilizing agent for oleaginous, physiologically active substances

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2382495 1995-02-13
JP7/23824 1995-02-13
JP7/231127 1995-09-08
JP23112795 1995-09-08

Publications (1)

Publication Number Publication Date
WO1996025053A1 true WO1996025053A1 (en) 1996-08-22

Family

ID=26361244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1996/000235 WO1996025053A1 (en) 1995-02-13 1996-02-06 Stabilizing agent for oleaginous, physiologically active substances

Country Status (1)

Country Link
WO (1) WO1996025053A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048475A1 (en) * 1999-02-18 2000-08-24 Fujisawa Pharmaceutical Co., Ltd. Masking agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05137498A (en) * 1991-11-21 1993-06-01 Nippon Oil & Fats Co Ltd Discoloration inhibitor for fisheries-processed food
JPH05176712A (en) * 1991-12-26 1993-07-20 Nippon Flour Mills Co Ltd Food containing casein phosphopeptide
JPH05244901A (en) * 1991-03-08 1993-09-24 Nippon Flour Mills Co Ltd Food containing casein phosphopeptide
JPH06228589A (en) * 1993-02-04 1994-08-16 Ueda Seiyu Kk Powdery fat and oil, and production thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05244901A (en) * 1991-03-08 1993-09-24 Nippon Flour Mills Co Ltd Food containing casein phosphopeptide
JPH05137498A (en) * 1991-11-21 1993-06-01 Nippon Oil & Fats Co Ltd Discoloration inhibitor for fisheries-processed food
JPH05176712A (en) * 1991-12-26 1993-07-20 Nippon Flour Mills Co Ltd Food containing casein phosphopeptide
JPH06228589A (en) * 1993-02-04 1994-08-16 Ueda Seiyu Kk Powdery fat and oil, and production thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048475A1 (en) * 1999-02-18 2000-08-24 Fujisawa Pharmaceutical Co., Ltd. Masking agent
KR100809911B1 (en) * 1999-02-18 2008-03-06 후소카가쿠코교 가부시키가이샤 Masking agent

Similar Documents

Publication Publication Date Title
Geranpour et al. Recent advances in the spray drying encapsulation of essential fatty acids and functional oils
Encina et al. Conventional spray-drying and future trends for the microencapsulation of fish oil
US9332774B2 (en) Microencapsulated oil product and method of making same
Kailasapathy Encapsulation technologies for functional foods and nutraceutical product development.
Wilson et al. Microencapsulation of vitamins
JP5439427B2 (en) Novel compositions containing carotenoids
CN104054849A (en) High-content medium chain triglyceride powdered oil and preparation method thereof
CN101115404B (en) Powder compositions
WO1993025302A1 (en) Emulsifier, emulsifying composition and powdery composition
US5853761A (en) Stabilizing agent for oleaginous, physiologically active substances
CN106715381B (en) Fatty acid composition and method for fortifying a nutritional product with fatty acids
EP1816919A1 (en) Nutrition bar or other food product and process of making
JP7458788B2 (en) Encapsulated nutritional and pharmaceutical compositions
CN115176861A (en) Instant protein powder and preparation method thereof
JPH09132775A (en) Stabilizing agent for oily physiologically active substance
JP2000508523A (en) Solid carrier particles coated with polyunsaturated fatty acids for food
EP2131678B1 (en) Allergen-free or dairy free lcpufa powdered compositions and the use thereof in food products and especially infant formulas
JP2013209493A (en) Powdery oil and fat, method for producing the same, powdery oil and fat-containing food, powdery oil and fat-containing oral medicinal product, and method for producing the powdery oil and fat-containing food
JPH1099046A (en) Production of powder composition
JPH0799932A (en) Health food containing phaffia coloring matter oil
EP2010013B1 (en) Oxidation-stable granulate containing unsaturated fatty acids
JPH05137506A (en) Powdered fats and oils and its production
WO1996025053A1 (en) Stabilizing agent for oleaginous, physiologically active substances
CN112998272A (en) Microcapsule with high content of phosphatidylcholine phospholipid and inulin polysaccharide and preparation method thereof
JP3027858B2 (en) Method for producing highly unsaturated fatty acid-containing composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1019970704705

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 08875601

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 1019970704705

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019970704705

Country of ref document: KR